Product Overview
[Drug Name]
Generic Name: Urapidil Sustained-Release Capsules
Trade Name: Kanglieping Urapidil Sustained-Release Capsules 30mg*12 Capsules
Pinyin Code: KangLiePing WuLaDiErHuanShiJiaoNang(HuiYuanZhuanXiang)30mg*12Li
[Main Ingredients]
The main ingredient of this product is urapidil. Chemical Name: 6-{3-[4-(0-methoxyphenyl)-1-piperazinyl]-propyl}-amino-1,3-dimethyluracil. Molecular Formula: C20H29N5O3. Molecular Weight: 387.48
[Properties]
This product is a capsule containing small white pellets.
[Indications/Main Functions]
1. Urinary dysfunction associated with benign prostatic hyperplasia. 2. Essential hypertension, renal hypertension, and hypertension caused by leucocyte tumors.
[Specifications]
30mg x 12 tablets
[Dosage and Administration]
1. Urinary dysfunction associated with benign prostatic hyperplasia (BPH). In adults, urapidil is typically started at 30mg (1 tablet) daily. If the effect is inadequate, the dose can be gradually increased to 60-90mg (2-3 tablets) daily over 1-2 weeks, administered orally twice daily. The dosage may be adjusted based on age and symptoms, but the maximum daily dose is 90mg (3 tablets). 2. Essential hypertension, renal hypertension, and hypertension caused by leukocytoma. In adults, urapidil typically starts with 30 mg (one tablet) daily. If the effect is not significant, the dosage can be gradually increased to 120 mg (four tablets) daily, divided into two oral doses, over a 1-2 week interval. The dosage can be appropriately increased or decreased based on age and symptoms.
[Adverse Reactions]
After using this product, patients may experience symptoms such as headache, dizziness, nausea, vomiting, sweating, irritability, fatigue, palpitations, irregular heartbeat, upper chest tightness, or dyspnea. These symptoms are caused by a rapid drop in blood pressure and usually resolve within minutes. Patients do not need to stop taking the drug. Allergic reactions (such as itching, redness, and rash) are rare. In rare cases, oral administration of this drug may result in decreased platelet counts, but serum immunological studies have not confirmed a causal relationship.
[Contraindications]
This product is contraindicated in patients with a history of allergic reactions to any of the components, aortic stenosis, or arteriovenous shunts (except for hemodynamically ineffective dialysis shunts).
[Precautions]
1. Because orthostatic hypotension may occur, blood pressure should be measured in the supine, standing, and sitting positions. Blood pressure should be controlled while sitting, taking into account changes in body position.
2. Initially taking this medication or when the dosage is increased rapidly, symptoms such as loss of consciousness, dizziness upon standing, headache, nausea, palpitations, and chest discomfort may occur. In particular, patients with urinary dysfunction associated with benign prostatic hyperplasia (BPH) may experience dizziness upon standing for up to three days during initial administration or when the dosage is increased rapidly. In such cases, appropriate measures such as placing the patient in the supine position should be taken, and symptomatic treatment should be provided as needed.
3. Initially taking this medication or when the dosage is increased rapidly, orthostatic hypotension may manifest as dizziness upon standing. Therefore, particular caution is advised for those engaged in hazardous work such as working at heights or driving a motor vehicle.
4. For patients with urinary dysfunction associated with BPH, it is important to note that this medication is not a causal treatment, but a symptomatic treatment. If this medication does not produce the expected effect after administration, other measures such as surgery should be considered.
5. Since this medication is a sustained-release formulation, do not chew the capsule granules during administration (this may cause side effects due to a rapid increase in blood drug concentration).
